Research and Markets has announced the addition of the "Celiac Disease - Pipeline Review, H2 2016" report to their offering.
Celiac Disease pipeline therapeutics constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities Institutes. Our latest report Celiac Disease - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Celiac Disease Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren's syndrome and Turner syndrome.
Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 8 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecule, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/2v8jrg/celiac_disease
View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005818/en/Business Wire
Last updated on: 17/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.